42 results about "Platelet Numbers" patented technology

Method and apparatus for reflected imaging analysis. Reflected imaging is used to perform non-invasive, in vivo analysis of a subject's vascular system. A raw reflected image (110) is normalized with respect to the background to form a corrected reflected image (120). An analysis image (130) is segmented from the corrected reflected image to include a scene of interest for analysis. The method and apparatus can be used to determine such characteristics as the hemoglobin concentration per unit volume of blood, the number of white blood cells per unit volume of blood, a mean cell volume, the number of platelets per unit volume of blood, and the hematocrit. Cross-polarizers can be used to improve visualization of the reflected image.

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and / or no-reflow phenomena and / or ischemia-reperfusion injury by administration of agent(s) modulating and / or preserving endothelial integrity. The compounds may be administered in combination with standard treatment of acute cardiovascular ischemic events such as Platelet inhibitors such as aspirin (ASA), Thienopyridins, GPIIb / IIIa inhibitors), Parenteral anticoagulants such as unfractioned heparin (UFH), bivalirudin, enoxaparin, and fondaparinux, Verapamil, Adenosine, Sodium nitroprusside, Nitroglycerin, Epinephrine, Beta-blockers and surgical methods such as percutaneous coronary intervention (PCI), PCI with thrombus aspiration, PCI with stents.

The present invention relates to compounds for treatment that protects the endothelium, prevent pathologic thrombus formation in the microcirculation and preserve platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

The present invention discloses the use of inhibitors and / or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).

The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and / or by agents modulating / preserving endothelial integrity and / or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death.

The invention discloses a pre-diluted vacuum blood collection tube, which comprises a tube body and a tube plug, wherein a tube cap is arranged at the outer side of the tube plug; the tube body, which is sealed, is under a vacuum state; scale marks, which are used for marking capacity of the tube body, are arranged on the outer wall of the tube body; scale values, indicated by the scale marks, range from 9mL to 10.5mL, and a minimum division value is 0.1mL; and 9mL of sodium chloride injection or compound electrolyte injection is contained in the tube body. The invention also discloses a method for measuring platelet number in a patient with EDTA-dependent pseudo-thrombocytopenia with the application of the pre-diluted vacuum blood collection tube. The pre-diluted vacuum blood collection tube provided by the invention is simple in structure; the pre-diluted vacuum blood collection tube is designed with the precise scale marks; venous blood is diluted by liquid which is free from an anticoagulation, so that autologous antigen in an anticoagulation-induced and activated platelet membrane glycoprotein GPIIb structure, and a purpose of inhibiting platelet aggregation is achieved; and the pre-diluted vacuum blood collection tube, through a mode of vacuum blood collection, simplifies operations and avoids pollution, caused by open blood collection, to operators and environment.

A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.

The invention discloses an application of an Akt inhibitor in preparation of a drug for treating platelet number decrease related diseases. Experiments prove that Akt regulates apoptosis and activation of platelet by activating cyclic adenosine monophosphate dependent phosphodiesterase and phosphodiesterase medicated PKA (protein kinase A), the apoptotic and activated platelet exposes phosphatidylserine, so that the phosphatidylserine is swallowed by macrophages. Inhibition or gene knockout of Akt or Akt medicated platelet activation and apoptosis or blocking of phosphatidylserine ectropion can stop clearance of antibody-bound platelet. Research indicates that the Akt inhibitor can be used for an anti-platelet membrane glycoprotein Ib alpha antibody to induce the treatment process of platelet number change related diseases and inhibit decrease of the number of platelets in peripheral circulation blood, so that the Akt inhibitor has the potential of being developed into novel platelet protection drugs and novel drugs for treating thrombocytopenic diseases and has great scientific research and economic value.

The invention discloses application of phosphatidylserine (PS) blocking agent to preparation of medicines for treating platelet number reduction related diseases. The invention proves that PS exposurecaused by apoptotic and activated platelets promotes that the platelets are eliminated in liver through experiments for the first time. Research proves that the platelets in the body of a patient suffering from thrombocytopenia are subjected to both activation and apoptosis, and apoptosis and activation cause the PS of the platelets to be exposed, so that the platelets are swallowed by phagocyticcells in the liver. Closing of the PS or blockage of PS extroversion can inhibit the platelets from being eliminated, which indicates that the PS blocking agent can take part in the treatment processof the platelet number change related diseases and can inhibit platelet number reduction in peripheral circulation blood. Therefore, the invention discloses a mechanism for eliminating the plateletsthrough the PS extroversion; furthermore, the blocking agent for inhibiting from eliminating PS exposure dependency platelets has the potential to be developed into novel platelets protective medicines and medicines for treating thrombocytopenia, and has great scientific research and economic value.

A method of increasing megakaryocytes and platelet numbers in a patient comprising the step of inhibiting SHIP expression, including SHIP's enzymatic activity and signaling functions, whereby normal blood clotting is induced.

The invention relates to an improved self platelet-rich plasma preparation method. A centrifugation method is adopted two times, centrifugation is performed under the condition of 850-1875 g for 11-15minutes for the first time, and centrifugation is performed under the condition of 100 g for 12 minutes for the second time. The method is simple, the platelet recovery rate is high, the cost is low,the preparation process is closed, the pollution risk is minimized, the product quantity and platelet number can be flexibly adjusted according to clinic demands, and a new method is provided for clinic preparation of self platelet-rich plasma.

The invention discloses application of PI3K (Phosphatidylinositol 3-Kinase) inhibitor to preparation of a medicine for treating related diseases of thrombocytopenia. Firstly, an experiment explores the effect of PI3K in a process of clearing platelets and proves that activation and apoptosis of the platelets of patients with the thrombocytopenia occur. An anti-Ibalpha antibody induces PI3K activation and Akt is activated after the PI3K is activated; the Akt is used for mediating the activation and apoptosis of the platelets. The Akt is used for regulating and controlling the apoptosis of the platelets through phosphodiesterase mediated protein kinase A. PS (Phosphatidylserine) is exposed after the apoptosis and activation of the platelets and is phagocytized by macrophages of liver. The activation of the PI3K is inhibited, the activation and apoptosis of the platelets are inhibited and the clearance of the platelets is stopped; the PI3K inhibitor can be used for treating the related diseases of platelet quantity changes and the thrombocytopenia in peripheral circulating blood is inhibited, so that the inhibitor has a potential of being prepared into novel platelet protection medicines and medicines for treating the thrombocytopenia, and extremely good scientific research and economic value.

The purpose of the present invention is to provide a hollow fiber membrane module by which cleaned platelets having a low total protein content and a high total platelet count can be prepared from a platelet suspension. Provided is a hollow fiber membrane module for separating foreign matters from a platelet suspension and thus cleaning platelets, said hollow fiber membrane module comprising: a housing which is provided with a platelet suspension inflow port, a cleaned platelet outflow port and a filtrate discharge port; and a hollow fiber membrane which is provided with holes not allowing the platelets to pass therethrough but allowing the foreign matters to pass therethrough, said hollow fiber membrane being positioned within the housing and filtering the platelet suspension, wherein, in the housing, the capacity of a space in the inflow side, which communicates with the platelet suspension inflow port and in which the platelet suspension before the filtration by the hollow fiber membrane is housed, is 30-400 mL and the water permeability of the module is 50-300 mL / Pa / hr.

The invention discloses a Zhuang medicine composition assisted in resisting lung cancer. The Zhuang medicine composition is characterized by being prepared from the following Zhuang medicinal materials: Nyarinngoux (Chinese name: baihuasheshecao), Gaeubwnhgauh (Chinese name: baiying), Byaekloekhauj (Chinese name: longkui), Buenqcilienz (Chinese name: banzhilian), Ginghgun (Chinese name: guangxi eshu), Fouxndoengz (Chinese name: shishangbai), Swnjgyaeujhenj (Chinese name: huanghuadaoshuilian), Raggongox (Chinese name: lugen), GO gyauhgujlanz (Chinese name: jiaogulan) and Lozhangoj (Chinese name: luohanguo). The Zhuang medicine composition is combined with chemical drugs for curing lung cancer, can reduce the toxic and side effects of inappetence caused by the chemical drugs, reduce the damage of the chemical drugs to immune organs, increase white blood cell count, blood platelet count, red blood cell count and hemoglobin count to reduce the inhibiting effect on myelosuppression, reduce the content of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase to alleviate the damage to liver functions and increase the tumor suppression function of the chemical drugs. Namely, the Zhuang medicine composition is combined with the chemical drugs for curing the lung cancer and has the effects of toxicity reducing and efficacy enhancing.

The invention provides a novel application of a recombinant ganoderma lucidum immunological regulation protein (rLZ-8) in treating thrombopenia. In the experiments of preventing and treating the thrombopenia of rats and dogs caused by cyclophosphamide, the rLZ-8 prepared from physiological saline carries out administration on an experimental animal model with lower thrombocytes, THPO and IL-6 areused as positive medicines, continuous administration is carried out, the number of the thrombocytes in blood is detected, the changes of the number of the thrombocytes before and after therapy are contrasted, and the medicine effect is analyzed. Compared with a model group, the rLZ-8 medicine group already obviously stimulates the thrombocyte proliferation of rats, Guinea pigs and dogs in the initial period (the 3rd day to the 5th day) of the administration, the difference is very obvious, the thrombocytes are recovered to a normal level in the middle period (the 7th day to the 10th day) of the administration, and the invention also obtains a very good effect in treating the thrombopenia of a Guinea pig experimental animal model caused by injecting anti-thrombocyte serum.

The disclosure features blood compatible articles and methods of making the articles. The methods include providing a substrate and forming a rough surface on the substrate. The rough surface includes a plurality of three-dimensionally curved features each having a radius of curvature of less than about 50 nm. The surface includes a sufficient concentration of features per unit area to limit blood coagulation activity on the substrate and to limit the number of platelets that adhere to the surface when the substrate is exposed to blood.

The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia.

The invention provides a high-speed blood platelet function detector and a method. The detector comprises a special sample transmission system, one or more independent detection units and a control unit. The special sample transmission system is used for conveying multiple sample cups to pass through all detection units simultaneously. The detector is provided with one or more detection units detecting the number and size of blood platelets in a blood sample along the special sample transmission system. According to the detector, all samples are mixed to be uniform continuously in the sample transmission process. After all the detection units of the detector detect the same quality control products, uniform automatic correction is conducted on all the detection units automatically, and theuniformity of the detection result of all detection units of the detector is guaranteed. The detector calculates the blood platelet function in the blood sample through the number of the blood platelets obtained before and after an aggregation agent is added and through detection on the blood sample added with the aggregation agent and not added with the aggregation agent.

The invention belongs to the technical field of terminal interaction, and discloses an orthopaedic preoperative examination and user terminal interaction system and method based on image analysis. Themethod comprises the following steps of collecting electrocardio data of a patient by utilizing an electrocardio instrument; collecting erythrocyte counting, hemoglobin, white blood cells, white blood cell classification counting and platelet data of the patient by using a blood detector; carrying out enhancement processing and encryption on the acquired CT image; and using the wireless transmitter for transmitting a wireless signal to be connected with the terminal module for wireless communication. According to the invention, self-adaptive enhancement of the bone CT image can be realized through the image enhancement module; the bone CT image with complex hue can be well recovered, and color confusion of the whole bone CT image is avoided; meanwhile, data encryption can be completed through the data encryption module without using existing modes such as RSA and random seeds, so that high-strength encryption of medical health information including personal privacy is realized.

Disclosed is a method for increasing the number of platelets in a mammal, which comprises administering to the mammal a platelet number increasing effective amount of an unbound, preferably a soluble, MPL receptor.

Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.

The invention relates to the technical field of blood anticoagulation methods, and discloses a blood anticoagulation method based on sodium citrate dehydrate and diethylenetriamine pentaacetic acid. The method comprises the following steps: (1) preparing instruments and materials, (2) collecting specimens, (3) preparing an anticoagulant, (4) collecting the specimens, (5) observing and comparing, (6) counting the specimens, and (7) obtaining a detection result: comparing two groups of data of 100 cases without PTCP in the action of a mixed anticoagulant of sodium citrate dihydrate and diethylenetriamine pentaacetic acid, and according to the change condition of numerical values, judging that the comparison of the observation group and the control group on the values of white blood cells, red blood cells, hemoglobin and platelets has no significant difference (P > 0.05), wherein compared with a manual method, the method has no obvious difference. According to the invention, sodium citrate dehydrate and diethylenetriamine pentaacetic acid are mixed for anticoagulation, so that a good anticoagulation effect on blood is achieved, blood cells and blood platelets can be accurately counted, and EDTA-PTCP is effectively avoided.

The invention discloses the use of a protein kinase A activator in the preparation of medicines for treating diseases related to platelet quantity reduction. The present invention explores the role of protein kinase A in the process of regulating platelet apoptosis through experiments for the first time, and finds that the activity of protein kinase A in platelets in patients with thrombocytopenia represented by idiopathic thrombocytopenic purpura, bacterial infection and diabetes decreases Studies have shown that protein kinase A regulates platelet apoptosis by regulating the phosphorylation of BAD 155 serine, and the activation of protein kinase A activity can inhibit the occurrence of endogenous platelet apoptosis. Protein kinase A activators can not only inhibit the occurrence of platelet apoptosis in vitro, but also increase the number of circulating platelets in experimental animals, suggesting that PKA activators can be used in the clinical treatment of thrombocytopenia by inhibiting platelet apoptosis. The potential of forming a new type of platelet protection drug has great scientific research and economic value.

The invention discloses perfluorocarbon albumin nanoparticles which comprise albumins and perfluorocarbon compounds, wherein the albumins coat the perfluorocarbon compounds, and the mass ratio of theperfluorocarbon compounds to the albumins is (4-40): 1. The perfluorocarbon albumin nanoparticles have good biological safety as a novel blood platelet inhibitor. The perfluorocarbon albumin nanoparticles which are administrated will induce great reduction of quantity of blood platelets in a human body, various functions of the blood platelets can be also inhibited obviously, and the perfluorocarbon albumin nanoparticles have relatively good clinical applications and practical treatment meaning.

An object of the present invention is to provide a hollow fiber membrane module that can produce washed platelets with a low total protein content and a high total platelet count from a platelet suspension. The present invention provides a hollow fiber membrane module, which is a hollow fiber membrane module that removes inclusions from platelet floating liquid and washes platelets. It is provided with a shell having a platelet floating liquid inlet, a platelet washing outlet and a filtrate discharge outlet. ; and, a hollow fiber membrane, the hollow fiber membrane has holes through which the above-mentioned platelets cannot pass but the above-mentioned inclusions can pass, which is arranged inside the above-mentioned shell to filter the above-mentioned platelet floating liquid; the volume of the inflow side space is 30~400mL , and the module water permeability is 50~300mL / Pa / hr. The inflow side space is connected with the platelet floating fluid inlet and accommodates the platelet floating fluid before being filtered by the hollow fiber membrane in the housing.

The invention belongs to the field of biological medicines, and relates to application of a vesicle in preparation of medicines for treating hemorrhagic diseases. The invention provides an application of a vesicle in preparation of a medicine for treating hemorrhagic diseases. The vesicle is an induced vesicle. The induced vesicle provided by the invention can exert a remarkable coagulation promoting effect in vitro, can remarkably improve the bleeding tendency after being injected in vivo, can be used for improving bleeding caused by blood coagulation factor deficiency, platelet number reduction and / or functional defects, for example, can be used for improving bleeding tendency of hemophilia, lupus erythematosus and treating Chediak-Higashi syndrome, can be discharged through skin and hair, has safety in vivo, and has good application prospects.

It has been demonstrated that GABRR1 is expressed on a subset of hematopoietic stem cells (HSC) and megakaryotic progenitor cells (MkP). MkP differentiation and reduction of the number of platelets in blood can be inhibited by inhibiting the GABRR1. GABRR1 overexpression or agonist treatment can significantly promote the generation of MkP and the growth of megakaryocytes.